Introduction {#Sec1}
============

Metzincins are a ubiquitously expressed family of multi-domain zinc (II)-dependent endopeptidases (Stocker and Bode [@CR209]), the members of which include well-known metalloproteases such as the matrix metalloproteases (MMPs) (Nagase and Woessner [@CR158]), a disintegrin and metalloproteases (ADAMs) (White [@CR231]), the ADAMs with a thrombospondin motif (ADAMTS) (Tang [@CR213]), the bacterial serralysins (Nakahama et al. [@CR159]) and proteases such as the astacins (including the meprins) (Bode et al. [@CR20]; Butler et al. [@CR31]). This superfamily of proteases is defined by the presence of a Zn^2+^ ion at the catalytic center, which is coordinated by three histidine residues in the zinc-binding consensus sequence HExxHxxGxxH that is present in all proteolytically active metzincins, and a characteristic, strictly conserved methionine-containing tight 1,4 beta turn forming a hydrophobic cleft for the catalytic zinc ion (Bode et al. [@CR21]). Catalysis of protein substrates is (most probably) carried out via a general base mechanism involving activation of a zinc-bound water molecule by the carboxylate group of the conserved glutamate residue in the catalytic pocket followed by attack of water on the polarized carbonyl group in the substrate's scissile bond (Browner et al. [@CR28]).

The main physiological function of these proteases was originally ascribed to the modulation and regulation of extracellular matrix (ECM) turnover by direct proteolytic degradation of the ECM proteins (e.g., collagen, proteoglycans and fibronectin) (Woessner [@CR236]). Another important function is the liberation of biologically active proteins such as cytokines, growth factors and chemokines from their membrane-anchored proforms (so-called shedding). More comprehensive "degradomics" approaches indicate, however, that this view is likely too limited (Butler and Overall [@CR30]). MMPs thus contribute to the generation of protein species with vastly differing activities from a single, original gene product.

Matrix metalloproteases {#Sec2}
=======================

Matrix metalloproteases or matrixins (see Table [1](#Tab1){ref-type="table"}) are a subfamily of metalloproteases, which consist of 23 distinct proteases in humans (24 in mouse). The first MMP was identified in 1962 as the protease responsible for the degradation of fibrillar collagen in tadpole tails during metamorphosis and was thus dubbed interstitial collagenase (Gross and Lapiere [@CR73]). After identification of a similar collagenase in human skin, this protease was renamed MMP-1. MMPs have since been identified as the major enzymes responsible for turnover of extracellular matrix by proteolytic degradation of virtually all proteinaceous components of the ECM (Woessner [@CR236]).Table 1Overview of the 23 identified human matrix metalloproteases and their common namesMMPAlternative nameMMPAlternative name1Collagenase-116Membrane type-3 MMPInterstitial collagenase2Gelatinase A17Membrane type-4 MMP72-kDa type IV collagenase3Stromelysin-119NoneTransin-1Human ortholog of *Xenopus* MMP-187Matrilysin20EnamelysinPump-18Collagenase-221NoneNeutrophil collagenaseHuman ortholog of *Xenopus* xMMP9Gelatinase B23Cysteine array MMP92-kDa type IV collagenaseFemalysinMMP-2210Stromelysin-224Membrane type-5 MMP11Stromelysin-325Membrane type-6 MMPLeukolysin12Macrophage metallo-elastase26Matrilysin-2/endometase13Collagenase-327None14Membrane type-1 MMP28Epilysin15Membrane type-2 MMP

MMPs are largely excreted proteins with several conserved domains (see Fig. [1](#Fig1){ref-type="fig"}). All MMPs contain the catalytic domain, which is shielded off in the inactive form of the enzyme by the prodomain. This propeptide interacts with the catalytic region through a conserved cysteine residue and the Zn^2+^ ion in the catalytic pocket (the so-called cysteine switch) (Nagase [@CR156]; Van Wart and Birkedal-Hansen [@CR221]). Except for MMP-7, MMP-23 and MMP-26, all MMPs contain a C-terminal hemopexin-like domain that functions primarily as a recognition sequence for the substrate (Murphy and Knauper [@CR153]). Although MMPs retain catalytic activity toward a wide range of substrates when missing this domain, the hemopexin domain, which is structured like a four-bladed propeller structure with each blade consisting of four antiparallel β-sheets and one α-helix, is an absolute necessity for the degradation of triple-helical collagens (Bode [@CR19]). The gelatinases (MMP-2 and -9) further contain a series of three fibronectin type II inserts in the catalytic domain, which facilitate binding of gelatine and collagen (Bode et al. [@CR22]).Fig. 1Schematic representation of the domain structure of metzincin proteases. *A* signal peptide, *B* prodomain, *C* catalytic domain, *D* hemopexin-like domain, *E* fibronectin type II insert, *F* transmembrane domain, *G* cytoplasmic tail, *H* disintegrin domain, *I* cysteine-rich domain, *J* EGF-like domain, *K* thrombospondin type I-like repeat, *L* spacer region

MMP function is regulated at several levels. Firstly, induction of gene expression is controlled by number growth factors and cytokines, and may be suppressed by transforming growth factor β and glucocorticoids (Nagase and Woessner [@CR158]; Vincenti [@CR222]). Recent insights indicate an important modulatory role of epigenetic processes in the expression of MMPs (Chernov et al. [@CR35]). Besides soluble factors, MMP expression may also be regulated by cell--cell contact or interaction of cells with ECM components such as EMMPRIN (extracellular matrix metalloprotease inducer or CD147) (Biswas et al. [@CR17]). The expressed MMPs are largely excreted as inactive proenzymes with the propeptide effectively limiting entrance into and catalysis of a substrate in the catalytic pocket by blocking the catalytic zinc (II) ion via the cysteine switch mechanism. Activation of proMMPs can occur through several mechanisms \[reviewed in Ra and Parks ([@CR183])\], all of which lead to disruption of the cysteine switch. Perhaps, the most important mechanism is proteolytic removal of the prodomain by other endopeptidases such as furin (Pei and Weiss [@CR178]). Removal of the prodomain of MMPs, which contains a furin-like proprotein convertase recognition site (RRKR or RxKR), has been described for nine MMPs including all membrane-type MMPs. Alternatively, the prodomain can be proteolytically removed by plasmin and other serine proteases, or even other MMPs. This mechanism is well described for MMP-2 where proMMP-2 binds the endogenous MMP inhibitor TIMP-2 (tissue inhibitor of metalloproteases 2). This complex in turn functions as a ligand for the membrane-bound MMP-14 (or membrane-type 1 MMP) leading to activation of MMP-2 (Cao et al. [@CR32]).

The cysteine switch may also be broken by chemical reactions, either physiologically by oxidation of cysteine by reactive oxygen species, or artificially by mercury-containing compounds such as 4-aminophenylmercuric acetate (APMA) or denaturing surfactants such as sodium dodecyl sulfate (SDS). This disruption of the thiol--zinc interaction leads to allosteric relocation of the prodomain leading to active forms of the enzyme with the propeptide still attached or to autoproteolytic removal of the relocated prodomain. MMPs are inhibited by the general protease inhibitor α~2~-macroglobulin and a small family of natural inhibitors specifically geared toward inhibiting metalloprotease activity. These TIMPs are a group of four proteins (21--30 kDa in size) that as a group effectively inhibit all MMPs in vivo (Gomez et al. [@CR71]).

Excreted MMPs are generally classified according to their substrate specificity, leading to four classes: the collagenases (MMP-1, -8 and -13), the gelatinases (MMP-2 and -9), the stromelysins (MMP-3, -10 and -11) and a heterogeneous group containing matrilysin (MMP-7), metallo-elastase (MMP-12), enamelysin (MMP-20), endometase (MMP-26) and epilysin (MMP-28). In this nomenclature, the membrane-anchored MMPs (MMP-14, -15, -16, -17, -24 and -25) are considered as a separate class. An alternate classification arranges the MMPs according to their domain structure (Sternlicht and Werb [@CR208]).

Soluble MMPs: collagenases {#Sec3}
==========================

MMP-1 {#Sec4}
-----

MMP-1 or collagenase-1 was the first described matrix metalloprotease and has sparked a large volume of research on the physiological and pathological role of MMPs. MMP-1 is a secreted enzyme and contains the hemopexin-like domain necessary for degradation of triple-helical collagens. ProMMP-1 is probably activated via a two-step proteolytic process involving either mast cell tryptase (Gruber et al. [@CR74]) or urokinase (Iba et al. [@CR86]) and MMP-3. Mature collagenase-1 can be found as two distinct forms: a major 57-kDa species and a minor, glycosylated 61-kDa form (Pardo and Selman [@CR172]). The active enzyme is inhibited by TIMP-1.

MMP-1 has a wide substrate specificity and is capable of degrading aggrecan, versican, perlecan, nidogen, serpins and tenascin-C (McCawley and Matrisian [@CR138]). Since MMP-1 does contain the hemopexin domain, it is one of the MMPs capable of proteolytic cleavage of fibrillar collagen leading to unwinding of the triple-helical structure that leaves collagen (or gelatine) highly susceptible to degradation by other proteases. Proteolysis by MMP-1 has also been implicated in the release of membrane-anchored proforms of insulin growth factor-binding proteins (IGFBP-3 and -5), IL-1β and L-selectin, among others (McCawley and Matrisian [@CR138]).

Since mice lack a clear ortholog of human MMP-1, definition of the physiological role by creating knockout mice has not been possible, but transgenic mice that express human MMP-1 are known to develop lung emphysema, indicating a possible role for MMP-1 in development of this disease (D'Armiento et al. [@CR39]). Other experiments with transgenic mouse strains have revealed development of skin disorders such as hyperkeratosis and bone growth retardation (D'Armiento et al. [@CR40]; Imai et al. [@CR89]). Since MMP-1 appears to play a key role in the turnover of ECM, deregulation of MMP-1 activity has been hypothesized to be involved in various diseases related to excessive or insufficient ECM turnover, such as arthritis (Vincenti et al. [@CR224]; Vincenti and Brinckerhoff [@CR223]), cancer (Benbow et al. [@CR15]; Brinckerhoff et al. [@CR27]), wound healing disorders (Muller et al. [@CR151]) and fibrotic diseases (Iredale et al. [@CR90]). MMP-1 expression has been reported to be sensitive to oxidative stress (Alge-Priglinger et al. [@CR2]) and cigarette smoke exposure in an ERK ½-dependent mechanism (Mercer et al. [@CR142]). MMP-1 activity may be regulated by redox mechanisms with low molecular weight thiols, such as glutathione and (homo)cysteine, inactivating MMP-1 by interaction with the catalytic Zn^2+^ ion and thus mimicking the cysteine switch, an effect that can be abrogated by oxidizing radicals (Koch et al. [@CR103]).

Although many studies have found a positive correlation between MMP-1 expression and disease, it has proven difficult to clearly identify MMP-1 as a systemic marker of the investigated disease. A recent study identified the level of circulating MMP-1 as a possible prognostic marker for the plaque burden in atherosclerosis, but the authors were unable to differentiate calcified and non-calcified plaques based solely on MMP-1 levels in serum (Lehrke et al. [@CR110]). Experiments with local sampling have proven more accurate, for instance in the analysis of MMP-1 in synovial fluid of rheumatoid arthritis patients, where MMP-1 levels correlated with inflammatory activity (Maeda et al. [@CR122]; Peake et al. [@CR175]).

MMP-8 {#Sec5}
-----

MMP-8 (neutrophil collagenase or collagenase-2) is very similar to MMP-1 in structure and physiological function, although subtle differences in substrate selectivity exist. MMP-8 has a stronger affinity toward type I collagen than MMP-1, while MMP-1 preferentially cleaves type III collagen (Balbin et al. [@CR5]). Neutrophil collagenase was first described in 1990 when it was cloned from neutrophils obtained from a patient with granulocytic leukemia (Hasty et al. [@CR76]). Contrary to MMP-1, MMP-8 is not released immediately after synthesis, but rather stored in specific granules that release the active enzyme on stimulation (Schettler et al. [@CR192]). As with MMP-1, MMP-8 can be activated by proteolytic removal of the propeptide by stromelysin-1 (MMP-3), but also by matrilysin (MMP-7) (Dozier et al. [@CR52]). The mature enzyme is 64 kDa in size, with glycosylation increasing the size to 75 kDa. Autoproteolytic degradation has been described, yielding a 40-kDa fragment, which retains catalytic activity but does not cleave fibrillar collagen. MMP-8 activity can be inhibited by TIMP-1 and TIMP-2 (Knauper et al. [@CR100]).

MMP-8 seems to have an important function during embryogenesis and postpartum remodeling of uterine tissue, as demonstrated by expression studies in mice (Balbin et al. [@CR5]). MMP-8 has also been implicated as one of the major contributors to connective tissue turnover in inflammation due to oxidative auto-activation of the enzyme (Weiss et al. [@CR230]). Experimental evidence has shown that purified MMP-8 is capable of degrading α~1~-proteinase inhibitor, which might link increased MMP-8 activity to the pathology associated with pulmonary emphysema (Desrochers et al. [@CR49]). Experiments with MMP-8 null mice demonstrate decreased migration of polymorphonuclear leukocytes into the airway lumen in a heterotopic airway transplant model, indicating a pivotal role of the protease in the development of obliterative bronchiolitis (Khatwa et al. [@CR97]).

The role of MMP-8 in cancer is interesting, since recent findings suggested this MMP to have a protective effect by suppressing tumor metastasis (Gutierrez-Fernandez et al. [@CR75]; Korpi et al. [@CR104]) and by increasing the susceptibility to oncolytic viruses (Mok et al. [@CR146]). On the other hand studies have identified MMP-8 as a promoter of ovarian tumor proliferation (Stadlmann et al. [@CR206]) and high MMP-8 expression seems to be an indicator for poor prognosis (Stenman et al. [@CR207]). This contradicting evidence of the role of MMP-8 in cancer is an indication of the complex, and so far still poorly understood biological roles of MMPs. MMP-8 is further involved in various inflammatory processes, such as atherosclerosis, where both expression as well as protease activity are higher in vulnerable plaques than in stable plaques (Herman et al. [@CR79]; Molloy et al. [@CR147]), indicating that MMP-8 may be useful as a marker for plaque instability in atherosclerosis.

MMP-13 {#Sec6}
------

MMP-13 (collagenase-3) is the latest human collagenase described in literature. This enzyme exhibits preference toward cleavage of type II collagen, effectively completing the substrate spectrum of the collagenases. Collagenase-3 was first cloned from breast cancer tissue in 1994 (Freije et al. [@CR64]). MMP-13 expression can be influenced by a wide range of hormones and cytokines, such as parathyroid hormone (indicative of the important role of MMP-13 in bone development), insulin-like growth factors I and II, platelet derived growth factor, basic fibroblast growth factor, transforming growth factor β1 (interestingly both up- and downregulates MMP-13 expression depending on the tissue), interleukin-1 and -6, tumor necrosis factor α and many more (Leeman et al. [@CR108]). ProMMP-13 can be activated by auto-proteolysis or propeptide removal by various other MMPs like stromelysin-1 (MMP-3), yielding a mature enzyme of 48 kDa, which in turn can be inhibited by TIMP-1, -2 and -3 (Knauper et al. [@CR101]). Active MMP-13 is a key factor in the activation pathway of several MMPs. Besides the TIMP route of inactivation, MMP-13 can bind to a specific receptor on the surface of osteoblasts and fibroblasts resulting in internalization and degradation of the protease (Barmina et al. [@CR11]).

MMP-13 plays an important role in bone development and remodeling, as may be anticipated from its capability to cleave type II collagen (a major component of cartilage). This rather specific function is reflected in a limited expression profile of MMP-13 during development and adulthood, which is restricted to developing skeletal tissue. MMP-13 has, contrary to the other collagenases, a relatively high specific activity toward gelatine, indicating that the proteolytic role of MMP-13 expands past the first step of cleavage of triple-helical collagens. Further identified substrates of MMP-13 include aggrecan and perlecan, transforming growth factor β, biglycan, the large protein species of tenascin-C, fibrillin-1 and -2, fibrinogen and two serpins (α~2~-antichymotrypsin and plasminogen activator inhibitor-2) (Leeman et al. [@CR108]).

MMP-13 expression has been regularly referred to in the literature as indicative of various cancerous processes including chondrosarcoma, breast cancer, head and neck tumors and melanoma (Balbin et al. [@CR6]). In all cases, high expression of MMP-13 seems to be related to aggressiveness of the tumor, and MMP-13 may even be required for metastasis of certain tumors as demonstrated for malignant melanoma (Zigrino et al. [@CR244]).

Regarding the important role of MMP-13 in bone turnover, it is not surprising that this enzyme has been linked to various bone-related diseases. Since MMP-13 degrades both type II collagen and aggrecan, it has been linked to cartilage destruction in rheumatoid and osteoarthritis (Burrage et al. [@CR29]). The specialized role of MMP-13 in bone development and disease has made it an attractive target for selective MMP-13 inhibitors as therapeutic compounds (Heim-Riether et al. [@CR78]; Hu et al. [@CR84]; Jungel et al. [@CR95]; Leeuwenburgh et al. [@CR109]).

Soluble MMPs: gelatinases {#Sec7}
=========================

MMP-2 {#Sec8}
-----

MMP-2 (gelatinase A, 72-kDa type IV collagenase) is one of the two described human gelatinases in the MMP family, named for their ability to proteolytically degrade gelatine (denatured collagen). MMP-2 is ubiquitously expressed as a 72-kDa proenzyme and subject to extensive glycosylation. Expression of MMP-2 is constitutive and most pro-inflammatory stimuli fail to increase the expression level since the gene, in contrast to that of MMP-9, lacks binding sites for pro-inflammatory transcription factors such as activator protein-1 (Templeton and Stetler-Stevenson [@CR214]).

The MMP-2 proenzyme is activated by forming a complex with TIMP-2 under appropriate stoichiometric conditions, which in turn is a substrate for the membrane-bound membrane type-1 MMP (MMP-14) that removes the prodomain of proMMP-2 by proteolytic cleavage (aided by free active MMP-2), yielding the truncated 64-kDa active enzyme (Deryugina et al. [@CR48]). If the concentration of TIMP-2 is too high, both MMP-14 and active MMP-2 will be inhibited, and no further activation will ensue. Besides this activation pathway, proMMP-2 can also be activated by thrombin and activated protein C (Nguyen et al. [@CR162]).

MMP-2 differs from other MMPs in that the catalytic domain contains cysteine-rich inserts that resemble the collagen-binding regions of the type II repeats in fibronectin. These inserts are required for binding and cleavage of collagen and elastin (Murphy et al. [@CR155]). MMP-2 is capable of cleaving gelatine, type I, IV and V collagens, elastin and vitronectin (Chakrabarti and Patel [@CR33]). Through their ability to degrade collagen in the vascular basal membranes, the gelatinases are involved in neovascularization (Nguyen et al. [@CR163]) both under physiological conditions and in pathologies such as tumor metastasis. The state of activation seems to be of crucial importance for the function of MMP-2 in angiogenesis. Recent research has demonstrated that the fully mature active form induces apoptosis in endothelial cells and inhibits neovascularization, while an intermediate activated form in complex with MMP-14 enhances cell survival and promotes angiogenesis (Shapiro et al. [@CR197]).

MMP-2 can also facilitate migration of cells by direct degradation of the basement membrane thus allowing infiltration of, for instance, neutrophils and lymphocytes, or liberation of chemoattractants (Nagase [@CR157]). This latter process, named 'ectodomain shedding', is an important physiological function of the membrane-bound ADAM proteases, but has also been described for many other members of the metzincin superfamily. MMP-2 has been known to be involved in both promoting and inhibiting inflammation by liberation of pro-inflammatory mediators \[for instance the active form of interleukin-1β (Schonbeck et al. [@CR193])\], proteolytic degradation of chemoattractants \[for instance, transforming monocyte chemoattractant protein-3 into the truncated form with antagonistic properties on the CC chemokine receptor (McQuibban et al. [@CR140])\] and a profound role in the chemotactic gradient that is necessary in the clearance of inflammatory cells from tissue (Corry et al. [@CR37]). Recent evidence from proteomics studies shows that the role of MMP-2 in processing signaling proteins may be much greater than originally anticipated, which, if confirmed for other MMPs, could lead to a paradigm shift in the physiological role of these proteases (Dean et al. [@CR46]; Dean and Overall [@CR45]).

Interestingly, MMP-2 knockout mice exhibit a normal phenotype under physiological conditions, although the animals do show different response patterns upon allergen challenge, which may be attributed to disturbance of the important role of clearing immune cells (Corry et al. [@CR37]). These findings indicate that MMP-2 function may be interchangeable with other metalloproteases, a hypothesis that is supported by the observation that expression of the second gelatinase, MMP-9, is greatly increased in MMP-2 null mice (Esparza et al. [@CR59]).

MMP-9 {#Sec9}
-----

MMP-9 (gelatinase B, 92-kDa type IV collagenase) was first discovered in neutrophils in 1974 (Sopata and Dancewicz [@CR204]). MMP-9 is expressed as a 92-kDa proenzyme, which can be activated to the 83-kDa mature enzyme. The larger size of MMP-9 relative to MMP-2 can be attributed to a heavily O-glycosylated collagen V-like insert that links the metalloprotease domain to the hemopexin-like domain (Mattu et al. [@CR133]). MMP-9 activation may be mediated by removal of the prodomain by serine proteases or other MMPs (Ogata et al. [@CR168]), or may be a direct response to oxidative stress that disrupts the cysteine switch (Maeda et al. [@CR123]). While a considerable overlap exists in the substrates degraded by MMP-2 and -9, MMP-9 is incapable of direct proteolysis of collagen I (Chakrabarti and Patel [@CR33]).

MMP-9 has been described to release the biologically active form of vascular endothelial growth factor (VEGF), which plays an important role in angiogenesis. This process is complemented by the direct proteolytic degradation of vascular basement membrane proteins, indicating that MMP-9 (even more than MMP-2) may play a crucial role in the formation of new blood vessels (Bergers et al. [@CR16]). Interestingly, the hemopexin domain of MMP-9 was reported to be an inhibiting factor in angiogenesis as demonstrated by decreased invasion of glioblastoma cells overexpressing the MMP-9 hemopexin domain in a xenograft model (Ezhilarasan et al. [@CR60]).

MMP-9 plays an important role in migration of immune cells as demonstrated by the reduced presence of neutrophils, lymphocytes and dendritic cells in brochoalveolar lavage fluid (BALF) of MMP-9 knockout mice after antigen challenge (Lemjabbar et al. [@CR112]). MMP-9 null mice show decreased fertility, since MMP-9 is crucial during several stages of the female reproductive cycle (implantation of the embryo and remodeling of endometrial tissue that occurs during the menstrual cycle) (Dubois et al. [@CR53]). Absence of MMP-9 also leads to disorders in bone development, specifically delayed bone ossification due to insufficient angiogenesis in growth plates (Vu et al. [@CR225]) and reduced osteoclast recruitment (Engsig et al. [@CR58]). The biological roles of MMP-9 have been extensively reviewed in (Van den Steen et al. [@CR220]).

MMP-9 is capable of processing cytokines and chemokines similarly to MMP-2. MMP-9 cleaves interleukin-8 to its more potent truncated form, activates IL-1β and transforming growth factor β (Chakrabarti and Patel [@CR33]). Proteomics techniques revealed a role of active MMP-9 in shedding β2 integrin from macrophages (Vaisar et al. [@CR219]). Whereas MMP-2 is primarily inhibited by TIMP-2, MMP-9 is mostly inhibited by TIMP-1 (Crocker et al. [@CR38]). Contrary to MMP-2, which is expressed ubiquitously under physiological conditions, MMP-9 is only present constitutively in neutrophils (Devarajan et al. [@CR50]), where it is stored in granules to be rapidly released after stimulation. Expression in many other cell types is inducible by (inflammatory) stimuli (Opdenakker et al. [@CR170]), is increased in malignant cell lines and correlates with their metastatic potential (Baruch et al. [@CR12]). Neutrophil-derived MMP-9 is distinguishable from other sources since it forms a covalent complex with neutrophil gelatinase B-associated lipocalin (NGAL) (Kjeldsen et al. [@CR98]).

The role of gelatinases in pathology has been studied extensively, especially in lung diseases \[reviewed in Chakrabarti and Patel ([@CR33])\] and cancer \[reviewed in e.g. Bjorklund and Koivunen ([@CR18]) and Klein et al. ([@CR99])\]. The amount of both gelatinases in BALF and sputum of patients suffering from chronic asthma is higher than in healthy individuals and this increase is hypothesized to be mainly due to gelatinases originating from eosinophils, neutrophils and epithelial cells (Maisi et al. [@CR124]; Mautino et al. [@CR137]). This increase may be responsible for the characteristic tissue remodeling events observed in chronic asthma such as thickening of the basement membrane, smooth muscle tissue hypertrophy and reduced epithelial thickness. MMP-2 does not seem to play an important role in the pathophysiology of acute asthma, but MMP-9 and the MMP-9/TIMP-1 ratio are increased in exacerbations of acute asthma (Lemjabbar et al. [@CR112]). This phenomenon may be explained by the presence of a pool of MMP-9 inside infiltrating neutrophils that is released during the asthmatic attack. Since neutrophils do not produce TIMP-1, degranulation leads to a strong increase in the local concentration of proteolytically active MMP-9, which may cause several of the symptoms observed in acute asthma, such as airway obstruction due to desquamation of epithelial cells and increased mucus production by goblet cells (Chakrabarti and Patel [@CR33]).

The role of gelatinases in the pathophysiology of chronic obstructive pulmonary disease (COPD) has not been clearly established, but excess protease activity plays an important role in the development and progression of the disease. Sputum and BALF of patients contain elevated concentrations of both MMP-2 and -9. MMP-9 may be an important factor in COPD development, since MMP-9 activity not only causes ECM destruction but has also been described to degrade α~1~-protease inhibitor leading to increased activity of neutrophil elastase and cathepsin G (Chakrabarti and Patel [@CR33]; Liu et al. [@CR116]). MMP-9 is further capable of promoting infiltration of neutrophils (loaded with MMP-9-containing granules) by production of the biologically more active truncated form of IL-8, causing a vicious circle of MMP-9 activity in the diseased lung. Presence and activity of gelatinases is elevated in many other pulmonary diseases, such as cystic fibrosis, bronchiectasis, acute respiratory distress syndrome (ARDS) and infections \[reviewed in Chakrabarti and Patel ([@CR33]) and Van den Steen et al. ([@CR220])\].

Gelatinases in cancer pathology {#Sec10}
===============================

The obvious relation of gelatinases to tumor metastasis and angiogenesis has led to a plethora of research papers on the role of MMP-2 and -9 in diverse malignant processes. This hypothesis was first affirmed by the observation that MMP-2 knockout mice show decreased tumor angiogenesis and progression (Itoh et al. [@CR91]). Since then, MMPs have been identified as important players in angiogenesis, growth and metastasis of tumors.

The development of a new vascular system is necessary for tumor growth, since without new blood vessels the size of a tumor will be restricted. Gelatinases are primarily involved in this process by enabling proteolytic degradation of the vascular basal membrane, opening the way for migration of endothelial cells to form new blood vessels (Risau [@CR186]). MMP-2 is further capable of cleaving laminin-5, which after degradation yields a cryptic site that increases endothelial cell migration (Risau [@CR186]) and the release of VEGF that stimulates angiogenesis, not only under physiological conditions but also during tumor development. Tumor growth can be stimulated by gelatinase activity, since MMP-2 and -9 have been shown to release growth factors (Levi et al. [@CR113]). Tumor metastasis is a process that involves the release of single tumor cells, migration of these cells to a blood vessel, penetration into the blood stream or lymph system and finally adhesion to vessel endothelium and extravasation into the tissue at the metastatic location. The ECM degrading properties of gelatinases are crucial in both exit of the metastatic cells from the bulk tumor as well as their entrance at the site of metastasis.

Increased gelatinase expression and activity has been described in hundreds of publications related to malignant diseases ranging from breast cancer (Somiari et al. [@CR203]), urogenital cancers (Maatta et al. [@CR120]; Sier et al. [@CR199]; Takemura et al. [@CR211]), brain tumors (Forsyth et al. [@CR62]), lung cancer (Nawrocki et al. [@CR161]), skin cancer (Pyke et al. [@CR181]), colorectal cancer (Murnane et al. [@CR152]) and many more. Interestingly, many authors have found a positive correlation between gelatinase expression or activity and the invasive potential of the tumor, again stressing the crucial role that MMP-2 and -9 play in metastasis. A comprehensive review of the literature on the role of gelatinases in individual cancers is beyond the scope of this article, but excellent reviews are available (Van den Steen et al. [@CR220]).

Besides in pulmonology and oncology, gelatinase activity is under investigation in several other research fields. MMP-2 has, for example, been identified as a possible target in cardiovascular disease, since it was identified as the protease responsible for degradation of the vasodilator peptide andrenomedullin, with one of the resulting fragment peptides having vasoconstrictive properties, possibly leading to hypertension (Martinez et al. [@CR128]).

Soluble MMPs: stromelysins {#Sec11}
==========================

MMP-3 {#Sec12}
-----

MMP-3 or stromelysin-1 was first described in 1985 as a 51-kDa protein secreted by rabbit fibroblasts (Chin et al. [@CR36]). MMP-3 could be distinguished from collagenases by the inability to degrade type I collagen. More or less simultaneously, a protease named transin was described in transformed rat cells, which later was identified to correspond to MMP-3 (Matrisian et al. [@CR129], [@CR130]). Stromelysins have a basic MMP structure, with a hemopexin-like domain. The 51-kDa latent proenzyme can be activated by proteolytic removal of the prodomain by, for instance, the serine proteases trypsin-2 (Moilanen et al. [@CR145]) and matriptase (Jin et al. [@CR93]), yielding a 43-kDa active enzyme in humans. MMP-3 is upregulated on exposure to interleukin 1β and downregulated by retinoic acid and dexamethasone (Saus et al. [@CR191]).

The substrate specificity of MMP-3 is broad and MMP-3 has been described to degrade many ECM proteins such as fibronectin, denatured collagens (gelatin), laminin and proteoglycans. MMP-3 is incapable of degrading triple-helical collagens, but can cleave the globular portion of type IV collagen (McDonnell and Matrisian [@CR139]). Besides degradation of ECM, component MMP-3 is also involved in the activation cascade of the gelatinases and MMP-13. The physiological function of MMP-3 is, surprisingly, not well described in literature, but is assumed to be mainly related to the turnover of extracellular matrix. MMP-3 is highly upregulated in mammary tissue during involution after the lactation period and seems to have a pro-apoptotic effect (Witty et al. [@CR235]).

In vitro experiments with cultured cells have identified a few membrane-bound signaling proteins that may be released by MMP-3 \[e.g., E-cadherin (Lochter et al. [@CR118]) and Fas ligand (Matsuno et al. [@CR132])\], but the physiological relevance of these findings is unclear. One well-described substrate of MMP-3 is plasminogen activator inhibitor-1 (PAI-1) (Lijnen et al. [@CR115]). ProMMP-3 can also form a complex with tissue-type plasminogen activator, which increases the activity of t-PA (Arza et al. [@CR3]). These findings may be indicative of an important regulatory function of MMP-3 in the fibrinolytic pathway.

MMP-3 has been described as an important factor in the development of arthritis (Green et al. [@CR72]), asthma (Dahlen et al. [@CR42]), aneurism (Silence et al. [@CR200]), impaired wound healing (Fray et al. [@CR63]), Alzheimer's disease (Yoshiyama et al. [@CR239]) and various cancers (Mercapide et al. [@CR141]; Wiesen and Werb [@CR232]). Recent insights and studies demonstrate that association of MMP-3 with disease states (especially cancer) is uncertain, as many newer studies do not find a positive correlation between MMP-3 and disease. This observation may be (partially) explained by the function of MMP-3 as an activator of other MMPs, which makes identification of the protease 'culprit' difficult.

MMP-10 {#Sec13}
------

The cloning of rat transin/MMP-3 in 1985 quickly led to the identification of a second stromelysin. This protease, named transin-2 (Breathnach et al. [@CR25]), and later identified in humans as stromelysin-2 (Muller et al. [@CR150]) or MMP-10, has 82% sequence homology with MMP-3 (Sirum and Brinckerhoff [@CR201]). MMP-10 is secreted as a 53-kDa proenzyme and is activated to a 47-kDa mature protease. Originally, MMP-10 production was thought to be relatively unaffected by stimuli such as cytokines and hormones (Brinckerhoff et al. [@CR26]), but recent studies have shown results that indicate the contrary (Barksby et al. [@CR10]).

The physiological function of MMP-10 is poorly understood, with only a handful of publications dealing with characterization of this protease. The in vitro substrate specificity seems similar to that of MMP-3, but catalytic activity toward type III, IV and V collagens is weaker (Murphy et al. [@CR154]). Contrary to MMP-3, MMP-10 is not produced by fibroblasts, but is expressed in keratinocytes which in turn do not produce MMP-3 (Saarialho-Kere et al. [@CR188]). MMP-10 seems to have an important role in skin wound healing and cellular migration, since it is primarily found at the front of the migrating epithelial 'tongue' (Madlener and Werner [@CR121]) and has been observed in migrating enterocytes in inflammatory bowel disease (Salmela et al. [@CR189]; Vaalamo et al. [@CR218]). MMP-10 is, in vitro, capable of processing laminin-5, which may be an additional mechanism by which the enzyme enables cellular migration (Krampert et al. [@CR105]). MMP-10 presence and activity at sites of resorption in developing bone have been demonstrated by histochemistry and casein in situ zymography and may play a role in remodeling events taking place during ossification (Bord et al. [@CR23]).

MMP-11 {#Sec14}
------

The third human stromelysin is MMP-11, which was first described in 1990 in a breast carcinoma cDNA library (Basset et al. [@CR13]). Although MMP-11 is often categorized as a stromelysin, it is very different from the other two proteases in this group. Production of MMP-11 is highest in fibroblasts and is particularly pronounced in remodeling tissues during the later stages of the process. MMP-11 has been associated with many physiological processes where ECM remodeling occurs, such as during embryonic development, the female reproductive cycle and wound healing. The 56-kDa MMP-11 proenzyme is activated intracellularly by furin (Pei and Weiss [@CR178]) or by paired basic amino acid cleaving enzyme-4 (PACE-4) (Bassi et al. [@CR14]) and is secreted as a 47-kDa active protease. The physiological role of MMP-11 is unclear, but differs significantly from other MMPs. No major ECM proteins such as collagens, gelatin and fibronectin can be degraded by MMP-11, and contrary to many other MMPs, it exhibits an anti-apoptotic effect. The biological mechanism underlying this effect is not known, but probably involves proteolytic cleavage of yet uncharacterized protein substrates that promote cell survival (Matziari et al. [@CR136]). Several possible substrates of MMP-11 have been identified, mainly protease inhibitors such as α~1~ proteinase inhibitor and α~2~ macroglobulin. MMP-11 further has a weak caseinolytic activity and has been shown to cleave insulin-like growth factor-binding protein-1 (IGF-BP-1) in a carcinoma cell line (Pei et al. [@CR179]). Recent research has demonstrated that, although MMP-11 does not cleave many ECM proteins, degradation of type VI collagen is one of its physiological functions that is related to inhibition of adipogenesis (Motrescu et al. [@CR149]).

The relatively narrow and peculiar substrate specificity of MMP-11 probably stems from a mutation that occurred in the highly conserved methionine turn. Whereas all other MMPs contain an MxP sequence in the Met turn, the proline is replaced by an alanine in MMP-11. This substitution has a profound effect on the structure of the S'1 selectivity pocket leading to greatly changed substrate specificity (Noel et al. [@CR166]).

Although the physiological role of MMP-11 is still poorly understood, the involvement of this enzyme in especially the early stages of the process of tumor formation and metastasis has been thoroughly investigated \[reviewed in Rio ([@CR185])\]. MMP-11 is rarely present in sarcoma tumors, but almost always expressed in carcinomas. An interesting observation is that MMP-11 is not produced by the malignant cells themselves, but by the surrounding mesenchymal cells. High levels of MMP-11 have predictive value for tumor aggressiveness and low survival rate. MMP-11 plays a role in early invasion of the surrounding tissue by tumor cells, a process that is dependent on the catalytic activity of the protease (Noel et al. [@CR167]). This is surprising since MMP-11 is not capable of degradation of the major ECM constituents. Cancer cells are able to stimulate nearby fibroblasts to produce MMP-11, a process that is associated with modification of the invaded ECM to a stroma phenotype by desmoplasia (Mari et al. [@CR127]). The anti-apoptotic effect of MMP-11 may play a role in establishment of the tumor and early survival. MMP-11-deficient tumors exhibit higher levels of apoptosis, and implantation of experimental tumors is lower in MMP-11 null mice (Boulay et al. [@CR24]). Although development of primary tumors is favorably affected by high MMP-11 levels, the metastatic potential of MMP-11 expressing tumors seems to be lower. In experiments with MMP-11 null mice, the number and size of secondary tumors was greater than in wild-type mice implanted with similar sized tumors, indicating a protective effect of MMP-11 (Rio [@CR185]).

Membrane-anchored MMPs: membrane-type MMPs {#Sec15}
==========================================

In addition to the soluble matrix metalloproteases, a small group of membrane-anchored MMPs has been described. The first member of this subfamily, MMP-14 or membrane type-1 MMP (MT1-MMP), was discovered in 1994 (Sato et al. [@CR190]) and cloning experiments have since revealed the existence of five additional MT-MMPs. The domain structure of MMP-14 is very similar to that of soluble MMPs (see Fig. [1](#Fig1){ref-type="fig"}) with the characteristic zinc-binding catalytic domain, the prodomain in the inactive proenzyme and a linked hemopexin-like domain. Most MT-MMPs are membrane anchored by a single-pass transmembrane domain followed by an intracellular cytoplasmic tail that contains three putative phosphorylation sites and is presumed to be important for localizing the enzyme on the cell surface (Lehti et al. [@CR111]). All MT-MMPs described contain the furin-like recognition site in their prodomain, allowing activation of the proenzyme by proteolytic removal of this domain by furin and other proprotein convertases (Yana and Weiss [@CR238]).

MMP-14 {#Sec16}
------

MMP-14 is present at the cell surface as a 55--60 kDa active protease, but may be processed by autocatalysis into smaller species of 45 kDa by proteolytic removal of the catalytic domain. This truncated form, which still contains the hemopexin-like domain, is assumed to play a role in autoregulation of MMP-14 catalytic activity (Toth et al. [@CR215]). The substrate specificity of MMP-14 is well described in literature \[reviewed in Barbolina and Stack ([@CR9])\]. The enzyme is capable of proteolytic degradation of type I, II and III collagens following the characteristic cleavage pathway used by collagenases (d'Ortho et al. [@CR41]), a finding that was corroborated by knockout experiments that confirmed the role of MMP-14 as an important interstitial collagenase. MMP-14 null mice die within 3 weeks, showing severe developmental abnormalities related to deficiencies in ECM processing, such as dwarfism, skeletal dysplasia and defective vascularization (Holmbeck et al. [@CR81]; Zhou et al. [@CR243]). Expression of MMP-14 may be regulated by the interaction of migrating cells with a three-dimensional collagen matrix, which triggers clustering of cell surface integrins and lead to transcriptional activation of the MMP-14 promotor (Ellerbroek et al. [@CR55]). Besides collagen, MMP-14 is capable of degradation of many other ECM components, such as fibronectin, vitronectin, tenascin, nidogen, aggrecan, fibrin, fibrinogen and laminin-5, leading to a possible stimulation of cellular migration as described above (Barbolina and Stack [@CR9]). Although the major proteolytic function of MMP-14 lies in the cleavage of extracellular substrates, some studies indicate a role in intracellular proteolysis after incorporation and accumulation of active MMP-14 in the centrosomal compartment, where it could contribute to development of mitotic spindle changes by degradation of pericentrin (Golubkov et al. [@CR69], [@CR70]). This mechanism could give rise to a role for MMP-14 in malignant transformation of cells. Intracellular protein--protein interaction between MMP-14 and adenosine nucleotide translocator has been described and is independent of the catalytic activity of MMP-14. This observation may implicate MMP-14 as a player in the regulation of the changing energy metabolism in malignant cells during tumor formation and migration (Radichev et al. [@CR184]). MMP-14 has further been identified as a cell surface sheddase and is capable of cleavage of many membrane-anchored proteins such as E- and N cadherin, integrins, hyaluronan receptor CD44, receptor activator of NF-κB ligand (RANKL) and several cell surface proteoglycans and their receptors (Barbolina and Stack [@CR9]). Ongoing research by proteomics techniques has revealed an ever-growing array of possible endogenous substrates of MMP-14 (Niiya et al. [@CR165]).

MMP-14 was originally identified as the extracellular protease responsible for activation of proMMP-2, and this process remains the best-described proteolytic function of the enzyme. In this process, one of the units of an MMP-14 dimer forms a trimeric complex with proMMP-2 and TIMP-2 at the cell surface leading to proteolytic removal of the propeptide of the proMMP-2 by the 'free' MMP-14 unit. Besides proMMP-2, also proMMP-13 (Knauper et al. [@CR102]) and proMMP-8 (Holopainen et al. [@CR82]) have been identified as possible targets for activation through this mechanism.

The role of MMP-14 in angiogenesis is well described and demonstrated by insufficient vascularization in knockout mice. MMP-14 is capable of degradation of the deposited fibrin matrix after vascular injury, effectively disrupting the repair mechanism and allowing endothelial cell invasion (Hiraoka et al. [@CR80]). MMP-14 may also be involved in migration of endothelial cells into the ECM, by proteolytic degradation of extracellular matrix proteins and by processing of various adhesion molecules (Galvez et al. [@CR67]). The formation and stabilization of the newly formed capillary tubes may also be dependent on MMP-14 activity, as demonstrated by impaired capillary formation in knockout models and RNA interference experiments (Robinet et al. [@CR187]). Finally, MMP-14 is able to release vascular endothelial growth factor A (VEGF-A) by shedding, again promoting neovascularization (Sounni et al. [@CR205]). MMP-14 together with MMP-15 may even be the determining factor in transforming cancer cells into the invasive phenotype, a process that is regulated by zinc-finger proteins such as Snail-1 (Ota et al. [@CR171]).

MMP-15 {#Sec17}
------

MT2-MMP (MMP-15) was first described in 1995 as the second member of the membrane-anchored MMP subfamily (Takino et al. [@CR212]). MMP-15 is a ubiquitously expressed enzyme with largely overlapping substrate specificity with MMP-14 (d'Ortho et al. [@CR41]). Although the physiological function of this protease is not as well described as for MMP-14, some studies have indicated a role in follicle rupture during ovulation (Ogiwara et al. [@CR169]) and the generation of tubular structures during angiogenesis (Lafleur et al. [@CR106]). MMP-15 has also anti-apoptotic properties (Abraham et al. [@CR1]). MMP-15 is capable of activating the MMP-2 proenzyme, but contrary to MMP-14 the activation mechanism is not dependent on the presence of TIMP-2, but rather on interaction with the hemopexin-like domain of MMP-2 (Morrison et al. [@CR148]).

Involvement of MMP-15 in pathology is still unclear, but considering the similarity with MMP-14 a role in cancer is expected. Indeed, MMP-15 is present in many investigated tumors, such as glioblastoma (Zhang et al. [@CR241]), non-small cell lung carcinoma (Atkinson et al. [@CR4]), and ovarian (Davidson et al. [@CR43]) and breast carcinoma (Ueno et al. [@CR216]), and seems to correlate with tumor invasiveness (Zhang et al. [@CR241]).

MMP-16 and MMP-24 {#Sec18}
-----------------

The two latest additions to the membrane-spanning MMP family are MT3-MMP (MMP-16), first described in 1997 (Matsumoto et al. [@CR131]), and MT5-MMP (MMP-24), first described in 1999 (Llano et al. [@CR117]). These enzymes are still poorly described in literature. The crystal structure of MMP-16 has been elucidated, and shows extensive similarity to MMP-14 (Lang et al. [@CR107]). MMP-16 activity is regulated by an autoproteolytic shedding process where a soluble form of the enzyme is released from the cell surface. The active enzyme shows high affinity to TIMP-3, as opposed to TIMP-1. Although originally anticipated to be a brain-specific enzyme (Pei [@CR176]), MMP-24 is possibly involved in remodeling events in endometrial lesions and endometriosis (Gaetje et al. [@CR65]). Like the other MT-MMPs, both MMP-16 and MMP-24 are capable of activating proMMP-2 (Wang et al. [@CR226]; Zhao et al. [@CR242]).

MMP-17 and MMP-25 {#Sec19}
-----------------

The final two MT-MMPs are structurally different from the other four with respect to their interaction with the cell membrane. MT4-MMP (MMP-17) (Pendas et al. [@CR180]) and MT6-MMP (MMP-25) (Pei [@CR177]) are linked to the cell membrane via a glycosyl-phosphatidyl-inositol (GPI) anchor, as opposed to containing a membrane-spanning domain. This anchor moiety is linked to the hemopexin-like domain by a 35--45 amino acid long hydrophilic linker, or stem. After production of the enzyme, this stem region is linked to a short hydrophobic tail, which is exchanged for a GPI anchor in the endoplasmic reticulum (Sohail et al. [@CR202]). The stem region further contains two or three cysteine residues, which may have a function in formation of dimers or trimers, as demonstrated by the presence of \~120 and \~180-kDa protein species of MMP-25 that are dissociated into the mature 57-kDa form of the enzyme under reducing conditions (Sun et al. [@CR210]). The GPI anchor gives these enzymes the possibility of interaction with lipid raft microstructures and may be involved in internalization and recycling of the enzymes (Sohail et al. [@CR202]). The TIMP-inhibition profile of the GPI-anchored MT-MMPs is different from the membrane-anchored MT-MMPs. While the latter are relatively resistant to inhibition by TIMP-1 due to incompatibility of the Thr^98^ residue with the S'1 selectivity pocket, MMP-17 and MMP-25 are effectively inhibited by TIMP-1, as well as by TIMP-2 and TIMP-3 (English et al. [@CR57]; Wang et al. [@CR227]). GPI-anchored MT-MMPs can be shed from various cells in exosomes, possibly leading to paracrine transfer to other cells (Itoh et al. [@CR92]).

Both MMP-17 and MMP-25 are capable of degrading ECM proteins, albeit MMP-17 in a limited fashion with cleavage demonstrated for gelatin, fibrin and fibrinogen. MMP-25 can cleave a wider range of ECM constituents including fibronectin, type IV collagen and proteoglycans (Kang et al. [@CR96]). In vitro experiments have revealed a multitude of possible substrates (including TNF alpha, indicating sheddase activity), but the physiological relevance is unclear \[reviewed in Sohail et al. ([@CR202])\]. Interestingly, MMP-17 is not able to activate proMMP-2 even in vitro, making this the only MT-MMP that lacks this trait (English et al. [@CR56]). MMP-25 does activate proMMP-2, but generates a different form of the active enzyme than the other MT-MMPs, indicating that the interaction between MMP-2 and MMP-25 is different (Nie and Pei [@CR164]). This activation mechanism is possibly dependent on the tight junction protein claudin-5, since cells that do not produce this protein are incapable of proMMP-2 activation by MMP-25 (Miyamori et al. [@CR143]). MMP-17 has been described as an activator of the aggrecanase ADAMTS-4 (Gao et al. [@CR68]).

Both GPI-anchored MT-MMPs are highly expressed in a wide variety of cancer cells ranging from breast carcinoma to glioma and colon cancers \[reviewed in Sohail et al. ([@CR202])\], but the clinical relevance of the presence of these proteins in malignant cells is not yet clear.

Soluble MMPs: matrilysins {#Sec20}
=========================

MMP-7 {#Sec21}
-----

MMP-7 (matrilysin) was originally described as PUMP-1 (putative uterine metalloprotease-1) in 1988, and was long considered a third member of the stromelysin family (MMP-11 was not yet known), although it appeared only distantly related to the other stromelysins (Muller et al. [@CR150]). The pump-1 gene identified from rat tumor cDNA cloning experiments was confirmed to code for a secreted metalloprotease in rat uterus (Woessner and Taplin [@CR237]), and later dubbed MMP-7. The mmp-7 gene contains a AP-1 promotor region, making it sensitive to upregulation by cytokines and growth factors (Gaire et al. [@CR66]). MMP-7 is the smallest human MMP (28-kDa proenzyme, 19-kDa mature active form), since it lacks the C-terminal hemopexin-like domain. This 'minimal domain structure' means that the activated enzyme comprises only the zinc-binding catalytic domain and results in an inability of MMP-7 to degrade intact collagens, again demonstrating the importance of the hemopexin-like domain in substrate recognition (Quantin et al. [@CR182]). MMP-7 is, however, capable of degrading a wide array of other ECM components such as gelatin, fibronectin, laminin and elastin. MMP-7 is capable of cleaving the prodomain of the gelatinases MMP-2 and -9 (Wilson and Matrisian [@CR233]), but its relevance under physiological conditions seems debatable considering the alternative, well-described activation pathway of proMMP-2. Finally, MMP-7 is a possible sheddase, with potential to liberate TNFα, Fas ligand, heparin-binding epidermal growth factor (HB-EGF), E-cadherin and β4-integrin (Ii et al. [@CR87]).

The originally described biological function of MMP-7 is the involvement in involution of the endometrium after pregnancy, but as later discovered, a unique function of MMP-7 seems to be its role in innate immunity. MMP-7 knockout mice exhibit decreased resistance to bacterial gastrointestinal infection and show decreased clearance of *E. coli* from the small intestine. MMP-7 is constitutively produced in the mucosal epithelium and may exert its function in mice by cleavage of pro-α-defensins yielding peptides with antibacterial properties. Co-localization of MMP-7 and pro-α-defensins in specialized epithelial Paneth cells seems to confirm this function (Wilson et al. [@CR234]). The role in mucosal host defense is further supported by the finding that exposure of cultured mucosal epithelial tissue or cells to pathogenic bacteria such as *E. coli* or *Pseudomonas aeruginosa* causes an increased production of MMP-7, and that germ-free bred mice show no expression of MMP-7 in the unchallenged gastro-intestinal tract (Lopez-Boado et al. [@CR119]). The strong induction of MMP-7 by bacterial challenge is an epithelium-specific function, since it does not occur in other cell types expressing MMP-7, and is exclusive for MMP-7 since no other MMPs are upregulated (Parks and Shapiro [@CR174]).

MMP-7 seems to be important in wound repair, since MMP-7 null mice show severe defects in epithelial wound healing which is probably due to a disrupted re-epithelialization (Dunsmore et al. [@CR54]). MMP-7 further enables migration of neutrophils through the epithelium during inflammation, since MMP-7 null mice show accumulation of neutrophils in the interstitium without them crossing over into the epithelium (Li et al. [@CR114]). The mechanism underlying this effect is probably the creation of a chemotactic gradient for neutrophils by cleavage of the proteoglycan syndecan-1 at the epithelial cell surface, causing liberation of the syndecan-bound chemokine KC that is produced by the epithelial cells after injury.

The role of MMP-7 in cancer has been well described. MMP-7 seems to occupy a unique place among MMPs with respect to cancer association, since it is one of the few MMPs that is actually produced by cancerous cells themselves, as opposed to the stroma-derived MMPs that are produced under stimulation by malignant cells (Ii et al. [@CR87]). As with other MMPs, MMP-7 has been identified in a wide range of tumors, and correlates with the aggressiveness of the tumor. In a malignant state, the activation of MMP-2 and -9 by MMP-7 may have an important function, and lead to increased invasiveness (Wang et al. [@CR228], [@CR229]). MMP-7, like MMP-3 may further promote tumor invasion by shedding of E-cadherin, leading to decreased cellular adhesion. Tumor growth is likely associated with MMP-7 sheddase activity, since the release of soluble HB-EGF by MMP-7 promotes cellular proliferation (Yu et al. [@CR240]). MMP-7 is further capable of cleaving all six members of the insulin-like growth factor-binding protein (IGF-BP) family, leading to increased availability of free IGF, which again promotes cancer cell growth and survival (Nakamura et al. [@CR160]). The activation of ADAM-28 is also attributed to MMP-7 (Mochizuki et al. [@CR144]), leading to increased degradation of IGF-BP3.

MMP-26 {#Sec22}
------

Recently, a novel matrilysin-like enzyme was identified in an endometrial tumor and named MMP-26 (matrilysin-2, endometase) (de Coignac et al. [@CR44]; Uria and Lopez-Otin [@CR217]). Like MMP-7, this is a minimal domain MMP missing the hemopexin-like C-terminus. This protease seems to have a more limited substrate specificity compared to MMP-7 and cannot degrade collagens, laminin and elastin (Park et al. [@CR173]). MMP-26 is unique among MMPs, since it is the only MMP described so far that does not have a functional cysteine switch mechanism to maintain the pro-enzyme in its latent conformation. Loss of the cysteine switch is attributed to the presence of a histidine residue N-terminal to the cysteine, a feature that is only observed in MMP-26 (Marchenko et al. [@CR126]; Marchenko and Strongin [@CR125]). Basal expression of MMP-26 is low except in endometrium, but is increased in many carcinoma cell lines (Marchenko et al. [@CR126]). The physiological function of MMP-26 remains to be elucidated.

Soluble MMPs: MMP-12 (macrophage metalloelastase) {#Sec23}
=================================================

MMP-12 was first described in 1981 (Banda and Werb [@CR7]) as murine metalloelastase and later identified as a member of the MMP family (Shapiro et al. [@CR195]). In 1993, a human ortholog was found (Shapiro et al. [@CR196]). MMP-12 was identified as an elastolytic metalloprotease produced by alveolar macrophages, which led to the trivial name (murine) macrophage metalloelastase (MME) or human macrophage elastase (HME). MMP-12 is expressed as a 54-kDa inactive proenzyme and is activated to a 45-kDa active enzyme by removal of the propeptide sequence. The mature enzyme can be further truncated to a 22-kDa active form on C-terminal processing mediated by serine proteases or through autocatalytic cleavage (Shapiro et al. [@CR196]). Autocatalytic removal of the C-terminal domain is possible in many other MMPs, but occurs very slowly in contrast to MMP-12, which is readily processed to the smaller form. Expression of MMP-12 is limited to macrophages and is not observed in blood monocytes. As the name reveals, a major substrate for MMP-12 is elastin, but MMP-12 is capable of degrading other ECM constituents (but not gelatin) (Banda et al. [@CR8]) and many non-matrix proteins in vitro (Chandler et al. [@CR34]).

MMP-12 null mice show normal development in the absence of inflammatory stress, but litter size is smaller, presumably due to abnormalities of the placenta during gestation. Macrophages obtained from knockout mice retain only a small fraction of their elastolytic activity, indicating that MMP-12 is indeed the most important elastin-degrading enzyme (in mice). MMP-12 is necessary for the penetration of macrophages through the basement membrane, as demonstrated by a complete inhibition of macrophage migration from MMP-12 null mice both in vitro and in vivo (Shipley et al. [@CR198]).

MMP-12 seems to play an intriguing role in cancer, which is different from other MMPs. MMP-12 is the primary protease responsible for proteolytic liberation of angiostatin from plasminogen. Angiostatin is a 38-kDa protein with anti-angiogenic properties due to the selective inhibition of endothelial cell proliferation. MMP-2 and -9 are also capable of degradation of plasminogen in vitro, but were found to make only a minor or no contribution to the production of angiostatin in an animal model (Dong et al. [@CR51]; Houghton et al. [@CR83]). This is another example of a protective effect of MMP activity in tumor genesis, an indication that knowledge of the actual biochemical mechanism of the involvement of a protease in disease is indispensable and cannot be replaced by mere association of expression levels in tumors.

Since human MMP-12 was first cloned from alveolar macrophages, it is not surprising that the role of MMP-12 in lung disease has been extensively studied. The involvement of MMP-12 in fibrotic processes in the lung is well established, but studies concerning the role of MMP-12 in emphysema are diffuse due to species differences between murine models and humans. In humans, it was reported that MMP-12 is not upregulated in macrophages of patients with emphysema compared to controls, but rather that macrophage-derived MMP-9 and MMP-1 are upregulated (Finlay et al. [@CR61]). MMP-12, on the other hand, was shown to be an absolute requirement for the development of emphysema after cigarette smoke exposure in a knockout animal model (Hautamaki et al. [@CR77]; Matute-Bello et al. [@CR134], [@CR135]). The interspecies difference may have caused bias with respect to the importance of MMP-12 since, although the failure of MMP-12 null mice to develop emphysema upon smoke exposure makes a more compelling point than determination of expression levels, MMP-12 seems to be the major MMP in murine macrophages, while human macrophages produce several MMPs (Parks and Shapiro [@CR174]). Evidence for a role of MMP-12 in lung function is based on a polymorphism in the MMP-12 gene that has been described to have predictive value for lung function decline in COPD (Joos et al. [@CR94]), a finding that was recently corroborated in a large association study between a single nucleotide polymorphism (SNP) in the MMP-12 promotor, which decreases MMP-12 expression, and a protective effect against lung function decline in asthma and COPD patients (Hunninghake et al. [@CR85]). Elevated MMP-12 levels have been measured in induced sputum of COPD patients (Demedts et al. [@CR47]), while a recent study has found only a slight increase of MMP-12 in stage 0 of the disease (Ilumets et al. [@CR88]). Proteolytic fragments of elastin have been implicated as chemotactic factors in macrophage recruitment (Senior et al. [@CR194]), giving a possible explanation for an early role of MMP-12 in emphysema development, with severe tissue destruction at later stages being mainly caused by other macrophage-derived proteases.

Conclusions {#Sec24}
===========

Matrix metalloproteases (MMPs) form a large family of enzymes with broad substrate specificity. While their initial role was mainly ascribed to turnover of the extracellular matrix, this view must likely be revised based on recent, more comprehensive studies. MMPs are involved in a delicate balance between proteolytic and anti-proteolytic activity to confine them in time and space. When this balance is disturbed, many disease phenotypes are observed ranging from tissue destruction in chronic inflammatory conditions, such as rheumatoid arthritis and COPD, to cancer metastasis and neurological disorders. The fact that MMPs degrade proteins into fragments with often new, completely different biological activities, supports the view of protein species.
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